The reduction in triglyceride-rich lipoproteins (TRL) seen in a Phase 2 study with retatrutide, the triple GIP, GLP-1, and glucagon receptor agonist in development in patients with type 2 diabetes, may have been due to concurrent reduction in ANGPTL3/8 levels.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
